Rayno Life Science Focus Stocks: ARIA, IMGN, PCYC 

Ariad (ARIA) Abstracts

Several data presentations will be made for Iclusig (Ponatinib)  for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2.

Immunogen (IMGN) Abstracts

The focus will be on two products using ADC (antibody-drug conjugate ) technology: IMGN853 utilizing a folate-receptor alpha targeting antibody in a pharmacokinetics (PK) and clinical evidence study study for epithelial  ovarian cancer (EOC) and solid tumors; and IMGN529 which contains a CD-37 targeting antibody in a dose finding Phase I study for treatment of NHL.

Pharmacyclics (PCYC) Abstracts

A initial Phase 3 study of IMBRUVICA as a single agent for CLL showing long term safety and efficacy and in combination with antibody targeting CD-20 in a Phase 1b/2 study.


Other oncology stocks to watch: AGIO, CELG, CLVS, EPZM, MDVN, PBYI, SGEN, XLRN

ASCO ’14 Preview from Adam Feuerstein: ABBV, GILD, PCYC.

Three Month Stock Performance ARIA, CLDX, IMGN, PCYC with IBB at $231.50, FBT at $75.71

Chart forAriad Pharmaceuticals Inc. (ARIA)



Pin It on Pinterest